These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 29477393)

  • 1. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].
    Garrison LP; Pauly MV; Willke RJ; Neumann PJ
    Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ISPOR's Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers.
    Solow B; Pezalla EJ
    Value Health; 2018 Feb; 21(2):166-168. PubMed ID: 29477395
    [No Abstract]   [Full Text] [Related]  

  • 6. ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.
    Perfetto EM
    Value Health; 2018 Feb; 21(2):169-170. PubMed ID: 29477396
    [No Abstract]   [Full Text] [Related]  

  • 7. ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.
    Burkholder R; Dougherty JS; Neves LA
    Value Health; 2018 Feb; 21(2):173-175. PubMed ID: 29477398
    [No Abstract]   [Full Text] [Related]  

  • 8. Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].
    Phelps CE; Lakdawalla DN; Basu A; Drummond MF; Towse A; Danzon PM
    Value Health; 2018 Feb; 21(2):146-154. PubMed ID: 29477392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.
    Sculpher M
    Value Health; 2018 Feb; 21(2):171-172. PubMed ID: 29477397
    [No Abstract]   [Full Text] [Related]  

  • 10. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.
    Garrison LP; Neumann PJ; Willke RJ
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis.
    Neumann PJ; Garrison LP; Willke RJ
    Value Health; 2022 Apr; 25(4):558-565. PubMed ID: 35279370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.